Faron, etusivu

releases and publications

Presentations at ESMO Immuno-Oncology Virtual Congress build case for CLEVER-1 as a new immune checkpoint target

Regulatory

Faron Pharmaceuticals to Participate in Upcoming Investor Conferences

Bexmarilimab (Clevegen) development update

Regulatory

Exercise of options  Issue of equity

Regulatory

First Results from WHO Solidarity Trial

Regulatory

Grant of options

Insider Transaction Regulatory

TR-1: S tandard form for notification of major holdings

Shareholder announcement Regulatory

Exercise of options

Regulatory

Half-year Report

Regulatory

MATINS trial data presented at ESMO

Regulatory
PreviousNext
Back to top